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Abstract
Background: Hepatic arterial infusion (HAI) chemotherapy is an effective treatment for patients with liver
malignancy. Extrahepatic perfusion (EHP) after HAI pump placement requires correction prior to starting
chemotherapy. The aim of this study was to define the origin of arterial branches causing EHP in order to
determine if alterations in surgical technique during pump placement might prevent EHP.
Methods: A prospectively maintained, single-centre HAI database was reviewed for all patients (2008–
2011) with EHP. The origin of arterial branches causing EHP was classified anatomically and patient
outcomes were analysed.
Results: Of the 327 patients with pumps implanted, 24 evidenced EHP. The arterial branch responsible
for EHP perfused the duodenum, pancreas and/or stomach. The branch responsible for EHP arose from
the proper hepatic artery (PHA), 1st, 2nd, or 3rd order hepatic artery branches in 7, 10, 5 and 2 patients,
respectively. The majority of branches beyond the PHA causing EHP (13/17) originated from the right
hepatic artery. In 18 patients, aberrant branches were successfully treated with embolization.
Conclusion: These findings provide the anatomic basis for prevention of up to one-third of the cases of
EHP intra-operatively, decreasing the number of patients who will require additional procedures for
correction of EHP post-operatively.
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Introduction
Hepatic artery infusion (HAI) chemotherapy for the treatment of
hepatic malignancy has been studied and used for three decades in
various tertiary cancer care facilities.1 A Cancer and Leukemia
Group B (CALGB) study of patients with unresectable metastatic
colorectal cancer to the liver demonstrated increased survival,
hepatic progression-free survival and response rates with HAI
chemotherapy compared with systemic chemotherapy.2 Three
randomized clinical trials documented a disease-free survival
advantage for patients with colorectal liver metastases who
received a combination of HAI and systemic chemotherapy com-
pared with systemic chemotherapy alone after liver resection.1–3
Reported complications after HAI pump placement and chemo-
therapy treatment include hepatitis, biliary sclerosis, bleeding
and infection.3 Aberrant perfusion of the non-hepatic territory,
referred to herein as extrahepatic perfusion (EHP), increases tox-
icity and needs to be avoided or corrected before initiation of HAI
chemotherapy.4–7
Surgical techniques for placement of HAI pumps in the setting
of normal8 and variant7 hepatic arterial anatomy have been
described previously. During pump placement, it is typically rec-
ommended that the common and proper hepatic arteries are
circumferentially dissected 2 cm proximal and distal to the origin
of the gastroduodenal artery (GDA).8 Complete circumferential
skeletonization of the hepatic artery and the GDA8 is thus
achieved and arterial branches to extrahepatic organs are ligated
and divided7 to eliminate the risk of EHP. Intra-operatively, EHP
is assessed by injection of methylene blue (direct visualization) or
fluorescein (Woods lamp visualization) via the side port of the
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HAI pump catheter. The patient is reassessed post-operatively by
nuclear medicine scintigraphy to rule out leakage, obstruction or
EHP before starting treatment with pump chemotherapy. The
organs most commonly affected by EHP include the stomach,
duodenum and/or pancreas.7
Although every effort is made to ligate all extrahepatic branches
during surgery, it occasionally fails or is technically not possible.7,8
In spite of a negative intra-operative methylene blue or fluorescein
study, nuclear scintigraphy may demonstrate EHP post-operatively.
When EHP is suspected on a post-operative nuclear medicine study,
patients are referred for angiographic evaluation. Once the respon-
sible branch is identified, transcatheter embolization can be per-
formed but in some cases is not technically possible.9 The goals of
this study were to define the anatomy of arterial branches causing
EHP and propose surgical strategies that might minimize the risk of
this complication.
Methods
A prospectively maintained database of patients who underwent
HAI pump placement between May 2008 and May 2011 was retro-
spectively reviewed. The data were collected and stored in com-
pliance with the Health Insurance Portability and Accountability
Act regulations, and a waiver of authorization was obtained from
the Memorial Sloan-Kettering Cancer Center Institutional Review
Board to allow analysis of patient information.
Before surgery, all patients underwent computed tomographic
angiography (CTA) to determine hepatic arterial anatomy. If there
was evidence of EHP intra-operatively, every effort was made to
identify and ligate the responsible arterial branch. In that situa-
tion, intra-operative re-testing for EHP was then performed.
In spite of meticulous surgical technique, EHP can either
persist or become evident only post-operatively. Within 2 weeks of
surgery, a nuclear medicine liver perfusion scan was performed
with technetium 99 (99Tc) sulfur-colloid intravenously and 99Tc
macroaggregated albumin via the implanted pump before the
device could be filled with chemotherapy. When scintigraphy
showed evidence of EHP, patients were referred for angiography
and embolization of responsible vessels if possible. The number of
HAI pumps salvaged by arterial embolization was recorded and
causes of unsuccessful embolization were analysed.
Only patients with evidence of EHP (n = 24) on post-operative
nuclear scintigraphy (n = 327) were included in the study. The
corresponding angiograms were reviewed by an experienced
interventional radiologist (K.B).Vascular anatomic variations were
recorded. An accessory hepatic artery was defined as a hepatic
branch that originated from an artery other than the proper hepatic
artery (PHA) and partially contributed to the blood supply of the
hemi-liver. A replaced hepatic artery was defined similarly except
that this branch completely supplied the hemi-liver. The arterial
branch causing EHP was identified and its origin was determined.
Branches causing EHP were divided into branches originating
from the PHA or distal to the PHA bifurcation. For patients with
aberrant branches distal to the PHA bifurcation, the order of
branching of the hepatic artery giving rise to the extrahepatic
branch was determined as shown in Fig. 1. Branches originating
from the right hepatic artery (RHA) or the left hepatic artery
(LHA) between the bifurcation of the PHA and the first branching
of the RHA or LHA were defined as 1st order. Branches arising distal
to the first branching of the RHA or the LHA but proximal to the
second branching of the hepatic vessels were classified as 2nd order.
All branches originating distal to the second branching of the
hepatic vessels were termed 3rd order branches. The distance
between the tip of the HAI catheter and the origin of the aberrant
vessel was estimated on angiography as either ≤2 cm or >2 cm.
Results
HAI pumps were placed in 327 patients during the 3-year study
period. Post-operatively and before using the pump, 24 (7.3%)
patients had evidence of EHP on nuclear liver scintigraphy.
Demographic, primary cancer diagnosis and hepatic resection
data for patients with EHP are summarized in Table 1.
Vascular anatomy and extrahepatic perfusion
Hepatic vascular anatomy data for these 24 patients with EHP
is summarized in Table 2. Twenty-one of the 24 patients had
Figure 1 Schematic illustration of extrahepatic branch order. 1st: first
order extrahepatic branch originates either from the left (LHA) or
right hepatic artery (RHA). 2nd: second order extrahepatic branch
originates distal to the first branching of the RHA or LHA but proxi-
mal to the second branching of the hepatic vessels; 3rd: third order
extrahepatic branch originates distal to the second branching of the
hepatic vessels; PHA: proper hepatic artery; CHA: common hepatic
artery; CT: celiac trunk; GDA: gastroduodenal artery
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standard celiac and hepatic vascular anatomy. The patients with
accessory hepatic artery branches had those ligated at the time of
operation. One patient had an accessory RHA originating from
the GDA beyond the take off of the LHA; in this patient, the LHA
was ligated and the HAI catheter was placed in the GDA up to the
origin of the RHA. The HAI catheter was inserted into the GDA in
all but one of the patients. In one patient, the HAI catheter was
placed into a large right gastric artery, which was judged to better
accommodate the catheter than the GDA. The GDA and right
gastric artery were ligated in this patient.
The duodenum (n = 19), pancreas (n = 12) and stomach (n = 7)
were the sites of EHP. Three out of 24 patients had simultaneous
perfusion of all three areas. Nine out of 24 patients had simulta-
neous perfusion of two areas, which included either the pancreas
and stomach (n = 5) or the duodenum and stomach (n = 4). In
Table 3 the origin of the branch causing EHP is shown. The
branch responsible for EHP arose from the PHA (Fig. 2a), 1st
(Fig. 2b), 2nd (Fig. 2c) and 3rd (Fig. 2d) order hepatic artery
branches in 7, 10, 5 and 2 of the 24 patients, respectively. It is
noteworthy that in 17 of these patients the vessel responsible for
EHP was relatively proximal and originated from the PHA or 1st
order branches (LHA or RHA). Of the 17 vessels distal to the PHA
responsible for EHP, 13 arose from the RHA. The distance
between the tip of the HAI catheter and the origin of the aberrant
vessel was estimated to be >2 cm in 15 patients and ≤2 cm in 9
patients. In retrospect, after specific review, 3 out of 24 patients
had an aberrant arterial branch that was apparent on pre-
operative CTA.
Management of extrahepatic perfusion
Eighteen of the 24 patients underwent successful embolization of
the aberrant arterial branch and the HAI pumps were successfully
used for chemotherapy. After failure of embolization in six
patients, two were successfully treated with surgical ligation of
aberrant arterial branches and four had technical complications
leading to permanent inability to administer pump chemo-
therapy. In two of these four patients, permanent pump failure
was attributed to an inability to remedy the cause of EHP: in one
patient the branch responsible for EHP could not be embolized
and in the other (n = 1) there was a celiac stenosis that was
responsible for EHP thought to be secondary to the median
arcuate ligament. The collateral flow from the superior mesenteric
artery to the celiac territory resulted in reversal of flow in the
common hepatic artery (CHA) with perfusion from the pump
catheter of the stomach, pancreas and spleen. In the remaining
Table 1 Demographic, disease, and treatment characteristics
Ntot = 24 N
Gender, female 11
Age (median, range) 62 (37–87)
Diagnosis
– CRLM 21
– CC 3
Surgery
– Pump only 8
– Pump & colectomy 2
– Pump & hepatectomy 9
– Pump & hepatectomy & RFA 5
Hepatic resection
– CL 2
– LH, CL, RFA 1
– LH, LW x1, RFA 1
– LH 1
– ERH, RFA 2
– LW, RFA 5
– RPS 2
CRLM, colorectal liver metastasis; CC, cholangiocarcinoma; CL, caudate
lobe; ERH, extended right hepatectomy; LH, left hemi-hepatectomy;
LW, liver wedge resection; RPS, right posterior sectorectomy; RFA,
radiofrequency ablation.
Table 2 Vascular anatomy and catheter insertion site
Anatomy (Ntot = 24) N
Standard 21
Accessory
– Right hepatic 1
– Left hepatic 1
RHA ‘replaced to GDA’ 1
Catheter Insertion site
– GDA 23
– RGA 1
GDA, gastroduodenal artery; RHA, right hepatic artery; RGA, right gastric
artery.
Table 3 Arterial branches causing extrahepatic perfusion
Branch N PHA LHA RHA RGA
Order
– PHA 7 7
– 1st 10 2 8
– 2nd 5 0 4 1
– 3rd 2 1 1
Distance
>2 cm 15 2 12 1
≤2 cm 9 7 1 1
Organ EHP
– Stomach 7 3 1 2 1
– Pancreas 12 5 2 4 1
– Duodenum 19 3 4 12
No. Patients 24 7 3 13 1
EHP, extrahepatic perfusion; PHA, proper hepatic artery; RHA, right
hepatic artery; LHA, left hepatic artery; RGA, right gastric artery; 1st, first
order branch; 2nd, second order branch; 3rd, third order branch.
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two patients, one developed perforation of the pump catheter into
the duodenum with active bleeding found during angiography,
and in the other (n = 1) dissection of the PHA occurred during
angiography. To summarize, 4 of 327 (1%) HAI pumps were
unusable as a result of EHP during the study period.
Discussion
HAI chemotherapy is used to improve outcomes in patients with
hepatic malignancies.10,11 When properly functioning, HAI pumps
maximize regional delivery of chemotherapy to the liver with
minimal systemic toxicity.10 EHP, although uncommon, can con-
tribute to HAI chemotherapy-related side effects. The anatomy of
extrahepatic vessels originating from the hepatic arteries is well
known and has been published in very large series by our group12
and others.13 However, non-hepatic arteries originating from
hepatic arteries and causing EHP after HAI pump placement has
yet not been reported.
The incidence of EHP was 7.3% (24/327) in the current series
and was comparable to previously published reports.6,7 The
majority of patients had conventional arterial anatomy. Several
factors might lead to EHP including redistribution of extrahepatic
blood flow to collateral channels after pump placement and
failure to ligate seemingly inconsequential arteries that ultimately
cause EHP. In the current series, almost one-third (7/24) of
branches causing EHP were found to arise from the PHA. These
branches are within the typical surgical dissection field and should
have been managed at the time of pump placement. The majority
of vessels responsible for EHP originate from the PHA or 1st order
hepatic arterial branches. Based on the present anatomic study,
we propose the techniques described as follows to prevent EHP
in approximately one-third of such patients. The GDA is
(a)
(b)
(c) (d)
Figure 2 (a) Common hepatic arteriogram demonstrates a small branch from the proper hepatic artery supplying the supra-pancreatic region
(arrow). PH: proper hepatic artery. (b) Common hepatic arteriogram reveals 1st order branch originating from the right hepatic artery (arrow).
PH: proper hepatic artery; RH: right hepatic artery; LH: left hepatic artery. (c) Common hepatic arteriogram shows 2nd order branch arising
from the right hepatic artery (arrow). PH: proper hepatic artery; RH: right hepatic artery; LH: left hepatic artery. (d) Common hepatic
arteriogram delineates 3rd order branch origin from the left hepatic artery (arrow). The patient had been treated with a right hepatectomy and
hepatic arterial pump placement. LH: left hepatic artery
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circumferentially cleared from the origin of the PHA to the supra-
pancreatic region. The PHA should be identified within the
hepatoduodenal ligament with subsequent circumferential dissec-
tion of the CHA, PHA and up to the first branching of the LHA
(1st order). The RHA should be dissected as far as is feasible and
safe given its most common course posterior to the common
hepatic bile duct. Small arterial branches should be tied and/or
clipped and divided. Great care must be taken to ligate the small
branches at the posterior aspect of the GDA. The right gastric
artery with small branching vessels must be cleared and divided to
avoid perfusion of the stomach. Given that the RHA typically has
a long course running posterior to the common hepatic bile duct
and that circumferential dissection may not be feasible in all
patients, we also recommend dissection and ligation of small
vessels along the superior border of the distal stomach and proxi-
mal duodenum. As these were the sites of perfusion for 2nd and 3rd
order branches, this dissection should divide branches to these
organs arising from more distal hepatic artery branching, poten-
tially diminishing the incidence of EHP. If there is evidence of
EHP on intra-operative pump perfusion test, further dissection of
the supra-pancreatic region and dissection of the PHA up to the
1st order branches are recommended.
Minimally invasive percutaneous placement of HAI pumps
has been described previously and has become more common.
Advantages of this technique include identification and
embolization of EHP branches at the time of pump placement,
eliminating the need for consecutive procedures.14,15 However,
operative placement allows a cholecystectomy (to prevent
chemotherapy-related cholecystitis), complete skeletonization of
the hepatic artery and its branches, and placement of the catheter
within the GDA (rather than the hepatic artery). Furthermore, an
explorative laparotomy is helpful in some cases to assess the extent
of disease and assess resectability.
In summary, almost one-third of arterial branches causing EHP
originate proximal to the PHA bifurcation and should be acces-
sible at the time of operation. A substantial number of occur-
rences of EHP might be avoided by complete circumferential
dissection and division of arterial branches from the PHA and its
1st order branches, when possible, combined with division of all
branches found along the superior border of the distal stomach
and proximal duodenum. This would avoid the need for, and
expense of, additional procedures to correct EHP post-operatively
and allow the patients to leave the hospital and begin treatment
earlier.
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